Next Round of GWAS a 'Wait-and-See Situation,' Says Illumina CEO

Though Illumina has been predicting a second round of association studies run on chips containing rare variant content, CEO Jay Flatley said that the market is "at the very beginning" of this new phase, which Illumina refers to as "rich GWAS."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.